0000846475--12-31 2021 Q2 ZYNEX INC ZYXI false NV 1600000 200000 1400000 100000 0 0 100000 200000 8000 0000846475 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000846475 zyxi:OperatingLeasesFiveMember 2021-04-01 2024-01-31 0000846475 zyxi:OperatingLeasesThreeMember 2020-11-01 2021-10-31 0000846475 zyxi:OperatingLeasesThreeMember 2020-03-09 2020-10-31 0000846475 zyxi:OperatingLeasesTwoMember 2020-01-01 2020-10-31 0000846475 zyxi:OperatingLeasesTwoMember 2019-03-11 2019-09-30 0000846475 zyxi:OperatingLeasesOneMember 2018-10-20 2019-10-19 0000846475 zyxi:OperatingLeasesOneMember 2017-10-20 2018-10-19 0000846475 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2021-04-01 2021-06-30 0000846475 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2021-01-01 2021-06-30 0000846475 us-gaap:AccountsReceivableMember 2021-01-01 2021-06-30 0000846475 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2020-04-01 2020-06-30 0000846475 us-gaap:AccountsReceivableMember 2020-01-01 2020-12-31 0000846475 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2020-01-01 2020-06-30 0000846475 zyxi:OperatingLeasesThreeMember 2021-11-01 2021-11-01 0000846475 zyxi:OperatingLeasesFiveMember 2021-04-09 2021-04-09 0000846475 2021-04-09 2021-04-09 0000846475 zyxi:OperatingLeasesTwoMember 2020-11-01 2020-11-01 0000846475 zyxi:OperatingLeasesFourMember 2020-10-01 2020-12-31 0000846475 zyxi:OperatingLeasesOneMember 2019-10-20 2019-10-20 0000846475 us-gaap:CommonStockMember 2021-03-08 0000846475 us-gaap:TreasuryStockMember 2021-04-01 2021-06-30 0000846475 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0000846475 us-gaap:TreasuryStockMember 2021-06-30 0000846475 us-gaap:RetainedEarningsMember 2021-06-30 0000846475 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000846475 us-gaap:TreasuryStockMember 2021-03-31 0000846475 us-gaap:RetainedEarningsMember 2021-03-31 0000846475 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000846475 2021-03-31 0000846475 us-gaap:TreasuryStockMember 2020-12-31 0000846475 us-gaap:RetainedEarningsMember 2020-12-31 0000846475 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000846475 us-gaap:TreasuryStockMember 2020-06-30 0000846475 us-gaap:RetainedEarningsMember 2020-06-30 0000846475 us-gaap:NoncontrollingInterestMember 2020-06-30 0000846475 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000846475 us-gaap:TreasuryStockMember 2020-03-31 0000846475 us-gaap:RetainedEarningsMember 2020-03-31 0000846475 us-gaap:NoncontrollingInterestMember 2020-03-31 0000846475 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000846475 2020-03-31 0000846475 us-gaap:TreasuryStockMember 2019-12-31 0000846475 us-gaap:RetainedEarningsMember 2019-12-31 0000846475 us-gaap:NoncontrollingInterestMember 2019-12-31 0000846475 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000846475 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000846475 us-gaap:CommonStockMember 2021-06-30 0000846475 us-gaap:CommonStockMember 2021-03-31 0000846475 us-gaap:CommonStockMember 2020-12-31 0000846475 us-gaap:CommonStockMember 2020-06-30 0000846475 us-gaap:CommonStockMember 2020-03-31 0000846475 us-gaap:CommonStockMember 2019-12-31 0000846475 us-gaap:WarrantMember 2020-01-01 2020-12-31 0000846475 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0000846475 us-gaap:WarrantMember 2021-06-30 0000846475 us-gaap:WarrantMember 2020-12-31 0000846475 us-gaap:EmployeeStockOptionMember 2020-12-31 0000846475 zyxi:StockIncentivePlan2017Member 2021-04-01 2021-06-30 0000846475 zyxi:StockIncentivePlan2017Member 2021-01-01 2021-06-30 0000846475 zyxi:StockIncentivePlan2017Member 2020-04-01 2020-06-30 0000846475 zyxi:StockIncentivePlan2017Member 2020-01-01 2020-06-30 0000846475 us-gaap:WarrantMember 2021-01-01 2021-06-30 0000846475 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0000846475 zyxi:TwoThousandAndFiveStockOptionPlanMember 2021-06-30 0000846475 zyxi:StockIncentivePlan2017Member 2021-06-30 0000846475 zyxi:EquityCompensationPlansNotApprovedByShareholdersMember 2021-06-30 0000846475 us-gaap:EmployeeStockOptionMember 2021-06-30 0000846475 zyxi:StockIncentivePlan2017Member 2017-06-30 0000846475 us-gaap:RestrictedStockMember 2021-06-30 0000846475 us-gaap:RestrictedStockMember 2020-12-31 0000846475 srt:ManagementMember us-gaap:RestrictedStockMember zyxi:StockIncentivePlan2017Member 2021-04-01 2021-06-30 0000846475 srt:ManagementMember us-gaap:RestrictedStockMember zyxi:StockIncentivePlan2017Member 2021-01-01 2021-06-30 0000846475 srt:ManagementMember us-gaap:RestrictedStockMember zyxi:StockIncentivePlan2017Member 2020-04-01 2020-06-30 0000846475 srt:ManagementMember us-gaap:RestrictedStockMember zyxi:StockIncentivePlan2017Member 2020-01-01 2020-06-30 0000846475 us-gaap:RestrictedStockMember 2021-01-01 2021-06-30 0000846475 zyxi:DevicesMember 2021-04-01 2021-06-30 0000846475 us-gaap:PublicUtilitiesInventorySuppliesMember 2021-04-01 2021-06-30 0000846475 zyxi:DevicesMember 2021-01-01 2021-06-30 0000846475 us-gaap:PublicUtilitiesInventorySuppliesMember 2021-01-01 2021-06-30 0000846475 zyxi:DevicesMember 2020-04-01 2020-06-30 0000846475 us-gaap:PublicUtilitiesInventorySuppliesMember 2020-04-01 2020-06-30 0000846475 zyxi:DevicesMember 2020-01-01 2020-06-30 0000846475 us-gaap:PublicUtilitiesInventorySuppliesMember 2020-01-01 2020-06-30 0000846475 zyxi:SalesRepDemoUnitsMember 2021-06-30 0000846475 zyxi:LeasedDevicesMember 2021-06-30 0000846475 us-gaap:VehiclesMember 2021-06-30 0000846475 us-gaap:LeaseholdImprovementsMember 2021-06-30 0000846475 us-gaap:FurnitureAndFixturesMember 2021-06-30 0000846475 us-gaap:EquipmentMember 2021-06-30 0000846475 zyxi:SalesRepDemoUnitsMember 2020-12-31 0000846475 zyxi:LeasedDevicesMember 2020-12-31 0000846475 us-gaap:VehiclesMember 2020-12-31 0000846475 us-gaap:LeaseholdImprovementsMember 2020-12-31 0000846475 us-gaap:FurnitureAndFixturesMember 2020-12-31 0000846475 us-gaap:EquipmentMember 2020-12-31 0000846475 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000846475 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000846475 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000846475 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000846475 zyxi:OperatingLeasesFourMember 2020-12-31 0000846475 zyxi:OperatingLeasesTwoMember 2019-06-01 0000846475 zyxi:OperatingLeasesTwoMember 2021-06-30 0000846475 zyxi:OperatingLeasesThreeMember 2021-06-30 0000846475 zyxi:OperatingLeasesOneMember 2021-06-30 0000846475 zyxi:OperatingLeasesFourMember 2021-06-30 0000846475 zyxi:OperatingLeasesFiveMember 2021-06-30 0000846475 zyxi:FinanceLeasesOfficeEquipmentTwoMember 2021-06-30 0000846475 zyxi:FinanceLeasesOfficeEquipmentThreeMember 2021-06-30 0000846475 zyxi:FinanceLeasesOfficeEquipmentOneMember 2021-06-30 0000846475 zyxi:FinanceLeasesOfficeEquipmentFourMember 2021-06-30 0000846475 zyxi:FinanceLeasesOfficeEquipmentFiveMember 2021-06-30 0000846475 srt:MinimumMember 2021-06-30 0000846475 srt:MaximumMember 2021-06-30 0000846475 zyxi:OperatingLeasesFiveMember 2021-04-09 0000846475 zyxi:OperatingLeasesFourMember 2020-09-17 0000846475 zyxi:OperatingLeasesThreeMember 2020-01-03 0000846475 zyxi:OperatingLeasesTwoMember 2019-03-11 0000846475 zyxi:OperatingLeasesOneMember 2017-10-20 0000846475 zyxi:FinanceLeasesOfficeEquipmentFourMember 2020-12-14 0000846475 zyxi:FinanceLeasesOfficeEquipmentThreeMember 2020-11-25 0000846475 zyxi:FinanceLeasesOfficeEquipmentFiveMember 2020-11-03 0000846475 zyxi:FinanceLeasesOfficeEquipmentTwoMember 2020-03-03 0000846475 zyxi:FinanceLeasesOfficeEquipmentOneMember 2019-09-20 0000846475 zyxi:EstimatedRateOneMember 2021-01-01 2021-06-30 0000846475 zyxi:SalesRepDemoUnitsMember 2021-04-01 2021-06-30 0000846475 zyxi:LeasedDevices1Member 2021-04-01 2021-06-30 0000846475 us-gaap:PropertyPlantAndEquipmentMember 2021-04-01 2021-06-30 0000846475 zyxi:SalesRepDemoUnitsMember 2021-01-01 2021-06-30 0000846475 zyxi:LeasedDevices1Member 2021-01-01 2021-06-30 0000846475 us-gaap:PropertyPlantAndEquipmentMember 2021-01-01 2021-06-30 0000846475 zyxi:SalesRepDemoUnitsMember 2020-04-01 2020-06-30 0000846475 zyxi:LeasedDevices1Member 2020-04-01 2020-06-30 0000846475 us-gaap:PropertyPlantAndEquipmentMember 2020-04-01 2020-06-30 0000846475 zyxi:SalesRepDemoUnitsMember 2020-01-01 2020-06-30 0000846475 zyxi:LeasedDevices1Member 2020-01-01 2020-06-30 0000846475 us-gaap:PropertyPlantAndEquipmentMember 2020-01-01 2020-06-30 0000846475 2020-06-30 0000846475 2019-12-31 0000846475 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0000846475 us-gaap:CommonStockMember 2021-01-01 2021-06-30 0000846475 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0000846475 us-gaap:CommonStockMember 2020-01-01 2020-06-30 0000846475 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-04-01 2021-06-30 0000846475 us-gaap:GeneralAndAdministrativeExpenseMember 2021-04-01 2021-06-30 0000846475 us-gaap:CostOfSalesMember 2021-04-01 2021-06-30 0000846475 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-06-30 0000846475 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-06-30 0000846475 us-gaap:CostOfSalesMember 2021-01-01 2021-06-30 0000846475 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-04-01 2020-06-30 0000846475 us-gaap:GeneralAndAdministrativeExpenseMember 2020-04-01 2020-06-30 0000846475 us-gaap:CostOfSalesMember 2020-04-01 2020-06-30 0000846475 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-06-30 0000846475 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-06-30 0000846475 us-gaap:CostOfSalesMember 2020-01-01 2020-06-30 0000846475 2020-01-01 2020-06-30 0000846475 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0000846475 2021-04-01 2021-06-30 0000846475 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000846475 2021-01-01 2021-03-31 0000846475 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0000846475 2020-04-01 2020-06-30 0000846475 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000846475 2020-01-01 2020-03-31 0000846475 2021-06-30 0000846475 2020-12-31 0000846475 2021-07-29 0000846475 2021-01-01 2021-06-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure utr:sqft zyxi:segment iso4217:USD utr:sqft zyxi:lease zyxi:item

Table of Contents

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

​

(Mark One)

| ☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

​

For the quarterly period ended: June 30, 2021

​

OR

​

| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

​

For the transition period from to

​

Commission file number 001-38804

​

Zynex, Inc.

(Exact name of registrant as specified in its charter)

​

NEVADA |  | 90-0275169
(State or other jurisdiction of | ​ | (IRS Employer
incorporation or organization) | ​ | Identification No.)
| ​ |
9655 Maroon Cir. | ​ | ​
Englewood, CO | ​ | 80112
(Address of principal executive offices) | ​ | (Zip Code)

​

(303) 703-4906

(Registrant’s telephone number, including area code)

​

(Former name, former address and former fiscal year, if changed since last report)

​

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class | Ticker symbol(s) | Name of each exchange on which registered
Common Stock, $0.001 par value per share | ZYXI | The Nasdaq Stock Market LLC

​

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No ☐

​

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧ No ☐

​

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

​

Large accelerated filer | ☐ | Accelerated filer | ☐
Non-accelerated filer | ☒ | Smaller reporting company | ☒
|  | Emerging growth company | ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ⌧

​

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

​

| ​ | ​
Class |  | Shares Outstanding as of July 29, 2021
Common Stock, par value $0.001 | ​ | 34,760,392

​

​

​

​

​

​

​

Table of Contents

ZYNEX, INC. AND SUBSIDIARIES

INDEX TO FORM 10-Q

​

|  |  | Page
PART I—FINANCIAL INFORMATION | 3
​ | ​ | ​ | ​
Item 1. | ​ | Financial Statements | 3
| ​ |  |
​ | ​ | Consolidated Balance Sheets as of June 30, 2021 (unaudited) and December 31, 2020 | 3
​ | ​ |  | ​
​ | ​ | Unaudited Consolidated Statements of Operations for the three and six months ended June 30, 2021 and 2020 | 4
​ | ​ |  |
​ | ​ | Unaudited Consolidated Statements of Cash Flows for the six months ended June 30, 2021 and 2020 | 5
​ | ​ |  |
​ | ​ | Unaudited Consolidated Statements of Stockholders’ Equity for the three and six months ended June 30, 2021 and 2020 | 6
​ | ​ |  |
​ | ​ | Unaudited Notes to Consolidated Financial Statements | 7
​ | ​ |  |
Item 2. | ​ | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 19
| ​ |  |
Item 3. | ​ | Quantitative and Qualitative Disclosures About Market Risk | 23
| ​ |  |
Item 4. | ​ | Controls and Procedures | 23
​ | ​
PART II—OTHER INFORMATION | 24
​ | ​ | ​ | ​
Item 1. | ​ | Legal Proceedings | 24
| ​ |  |
Item 1A. | ​ | Risk Factors | 24
| ​ |  |
Item 2. | ​ | Unregistered Sales of Equity Securities And Use of Proceeds | 24
| ​ |  |
Item 3. | ​ | Defaults Upon Senior Securities | 24
| ​ |  |
Item 4. | ​ | Mine Safety Disclosures | 24
| ​ |  |
Item 5. | ​ | Other Information | 24
| ​ |  |
Item 6. | ​ | Exhibits | 25
​ | ​
SIGNATURES | 26

​

​

​

2

​

Table of Contents

PART I. FINANCIAL INFORMATION

​

ITEM 1. FINANCIAL STATEMENTS

ZYNEX, INC.

CONSOLIDATED BALANCE SHEETS

(AMOUNTS IN THOUSANDS, EXCEPT NUMBER OF SHARES)

(unaudited)

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | June 30, | ​ | December 31,
​ |  | 2021 |  | 2020
ASSETS | ​ | ​ | ​ | ​ | ​ | ​
Current assets: |  | ​ |  |  | ​ |
Cash | ​ | $ | 32,330 | ​ | $ | 39,173
Accounts receivable, net | ​ |  | 18,310 | ​ |  | 13,837
Inventory, net | ​ |  | 9,951 | ​ |  | 8,635
Prepaid expenses and other | ​ |  | 1,188 | ​ |  | 1,378
Total current assets | ​ |  | 61,779 | ​ |  | 63,023
​ | ​ | ​ | ​ | ​ | ​ | ​
Property and equipment, net | ​ |  | 2,355 | ​ |  | 1,925
Operating lease asset | ​ | ​ | 18,111 | ​ | ​ | 5,993
Finance lease asset | ​ | ​ | 429 | ​ | ​ | 321
Deposits | ​ |  | 584 | ​ |  | 347
Deferred income taxes | ​ |  | 440 | ​ |  | 566
Total assets | ​ | $ | 83,698 | ​ | $ | 72,175
​ | ​ | ​ | ​ | ​ | ​ | ​
LIABILITIES AND STOCKHOLDERS' EQUITY | ​ |  |  | ​ |  |
Current liabilities: | ​ |  |  | ​ |  |
Accounts payable and accrued expenses | ​ | ​ | 2,652 | ​ | ​ | 4,717
Operating lease liability | ​ |  | 2,367 | ​ |  | 2,051
Finance lease liability | ​ |  | 106 | ​ |  | 77
Income taxes payable | ​ |  | 403 | ​ |  | 280
Accrued payroll and related taxes | ​ |  | 3,363 | ​ |  | 2,992
Total current liabilities | ​ |  | 8,891 | ​ |  | 10,117
Long-term liabilities: | ​ |  |  | ​ |  |
Operating lease liability | ​ |  | 17,136 | ​ |  | 4,920
Finance lease liability | ​ | ​ | 371 | ​ | ​ | 283
Total liabilities | ​ |  | 26,398 | ​ |  | 15,320
​ | ​ | ​ | ​ | ​ | ​ | ​
Commitments and contingencies | ​ |  | ​ | ​ |  | ​
Stockholders' equity: | ​ |  |  | ​ |  |
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of June 30, 2021 and December 31, 2020 | ​ |  | — | ​ |  | —
Common stock, $0.001 par value; 100,000,000 shares authorized; 36,204,189 issued and 34,767,899 outstanding as of June 30, 2021 and 36,126,698 issued and 34,791,931 outstanding as of December 31, 2020 | ​ |  | 37 | ​ |  | 36
Additional paid-in capital | ​ |  | 37,697 | ​ |  | 37,235
Treasury stock 1,211,399 shares, at June 30, 2021 and 1,071,220 shares at December 31, 2020, respectively, at cost | ​ |  | (5,966) | ​ |  | (3,846)
Retained earnings | ​ |  | 25,532 | ​ |  | 23,430
Total stockholders' equity | ​ |  | 57,300 | ​ |  | 56,855
Total liabilities and stockholders' equity | ​ | $ | 83,698 | ​ | $ | 72,175

​

The accompanying notes are an integral part of these condensed consolidated financial statements.

​

3

​

Table of Contents

ZYNEX, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS
(AMOUNTS IN THOUSANDS, EXCEPT PER SHARE DATA)

(unaudited)

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the Three Months Ended June 30, | ​ | For the Six Months Ended June 30, | ​
​ |  | 2021 |  | 2020 |  | 2021 |  | 2020 | ​
NET REVENUE |  | ​ |  |  | ​ |  | ​ | ​ |  |  | ​ |  | ​
Devices | ​ | $ | 7,828 | ​ | $ | 4,281 | ​ | $ | 14,193 | ​ | $ | 7,725 | ​
Supplies | ​ |  | 23,194 | ​ |  | 14,982 | ​ |  | 40,956 | ​ |  | 26,766 | ​
Total net revenue | ​ |  | 31,022 | ​ |  | 19,263 | ​ |  | 55,149 | ​ |  | 34,491 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
COSTS OF REVENUE AND OPERATING EXPENSES | ​ |  | ​ | ​ |  | ​ | ​ |  |  | ​ |  |  | ​
Costs of revenue - devices and supplies | ​ |  | 7,267 | ​ |  | 4,061 | ​ |  | 13,153 | ​ |  | 7,462 | ​
Sales and marketing | ​ |  | 13,752 | ​ |  | 6,800 | ​ |  | 27,579 | ​ |  | 12,384 | ​
General and administrative | ​ | ​ | 6,188 | ​ | ​ | 4,317 | ​ | ​ | 11,683 | ​ | ​ | 8,102 | ​
Total costs of revenue and operating expenses | ​ |  | 27,207 | ​ |  | 15,178 | ​ |  | 52,415 | ​ |  | 27,948 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Income from operations | ​ |  | 3,815 | ​ |  | 4,085 | ​ |  | 2,734 | ​ |  | 6,543 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Other expense | ​ |  |  | ​ |  |  | ​ |  |  | ​ |  |  | ​
Interest expense | ​ |  | (45) | ​ |  | (5) | ​ |  | (54) | ​ |  | (9) | ​
Other expense, net | ​ |  | (45) | ​ |  | (5) | ​ |  | (54) | ​ |  | (9) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Income from operations before income taxes | ​ |  | 3,770 | ​ |  | 4,080 | ​ |  | 2,680 | ​ |  | 6,534 | ​
Income tax expense | ​ |  | 962 | ​ |  | 1,063 | ​ |  | 578 | ​ |  | 580 | ​
Net Income | ​ | $ | 2,808 | ​ | $ | 3,017 | ​ | $ | 2,102 | ​ | $ | 5,954 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net income per share: | ​ |  | ​ | ​ |  | ​ | ​ |  |  | ​ |  |  | ​
Basic | ​ | $ | 0.08 | ​ | $ | 0.09 | ​ | $ | 0.06 | ​ | $ | 0.18 | ​
Diluted | ​ | $ | 0.08 | ​ | $ | 0.09 | ​ | $ | 0.06 | ​ | $ | 0.17 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Weighted average basic shares outstanding | ​ |  | 34,810 | ​ |  | 33,283 | ​ |  | 34,824 | ​ |  | 33,098 | ​
Weighted average diluted shares outstanding | ​ |  | 35,583 | ​ |  | 34,454 | ​ |  | 35,629 | ​ |  | 34,329 | ​

​

The accompanying notes are an integral part of these condensed consolidated financial statements.

​

4

​

Table of Contents

ZYNEX, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(AMOUNTS IN THOUSANDS)

(unaudited)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the Six Months Ended June 30, | ​
​ |  | 2021 |  | 2020 | ​
CASH FLOWS FROM OPERATING ACTIVITIES: |  | ​ |  |  | ​ |  | ​
Net income | ​ | $ | 2,102 | ​ | $ | 5,954 | ​
Adjustments to reconcile net income to net cash (used in) operating activities: | ​ |  |  | ​ |  |  | ​
Depreciation | ​ |  | 1,094 | ​ |  | 537 | ​
Non-cash reserve (recoveries) | ​ | ​ | (35) | ​ | ​ | (310) | ​
Stock-based compensation | ​ |  | 509 | ​ |  | 1,076 | ​
Non-cash lease expense | ​ |  | 414 | ​ |  | 8 | ​
Provision for deferred income taxes | ​ |  | 126 | ​ |  | 110 | ​
Change in operating assets and liabilities: | ​ |  | ​ | ​ |  |  | ​
Accounts receivable | ​ |  | (4,473) | ​ |  | (1,431) | ​
Prepaid and other assets | ​ |  | 191 | ​ |  | (489) | ​
Accounts payable and other accrued expenses | ​ |  | (1,570) | ​ |  | 189 | ​
Inventory | ​ |  | (2,398) | ​ |  | (2,408) | ​
Deposits | ​ |  | (238) | ​ |  | 47 | ​
Net cash (used in)/ provided by operating activities | ​ |  | (4,278) | ​ |  | 3,283 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
CASH FLOWS FROM INVESTING ACTIVITIES: | ​ |  |  | ​ |  |  | ​
Purchase of property and equipment | ​ |  | (354) | ​ |  | (654) | ​
Net cash (used in) investing activities | ​ |  | (354) | ​ |  | (654) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
CASH FLOWS FROM FINANCING ACTIVITIES: | ​ |  |  | ​ |  |  | ​
Payments on finance lease obligations | ​ |  | (44) | ​ |  | (27) | ​
Purchase of treasury stock | ​ |  | (2,120) | ​ |  | — | ​
Proceeds from the issuance of common stock on stock-based awards | ​ | ​ | 89 | ​ | ​ | 274 | ​
Taxes withheld and paid on employees' equity awards | ​ | ​ | (136) | ​ | ​ | — | ​
Net cash (used in)/provided by financing activities | ​ |  | (2,211) | ​ |  | 247 | ​
Net (decrease)/ increase in cash | ​ |  | (6,843) | ​ |  | 2,876 | ​
Cash at beginning of period | ​ |  | 39,173 | ​ |  | 14,040 | ​
Cash at end of period | ​ | $ | 32,330 | ​ | $ | 16,916 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Supplemental disclosure of cash flow information: | ​ |  |  | ​ |  |  | ​
Cash paid for interest | ​ | $ | (54) | ​ | $ | (9) | ​
Cash paid for rent | ​ | $ | (1,069) | ​ | $ | (779) | ​
Cash paid for income taxes | ​ | $ | (335) | ​ | $ | (660) | ​
Supplemental disclosure of non-cash investing and financing activities: | ​ |  | ​ | ​ |  | ​ | ​
Right-of-use assets obtained in exchange for new operating lease liabilities | ​ | $ | 13,247 | ​ | $ | 1,433 | ​
Right-of-use assets obtained in exchange for new finance lease liabilities | ​ | $ | 162 | ​ | $ | 72 | ​
Inventory transferred to property and equipment under lease | ​ | $ | 967 | ​ | $ | 343 | ​
Inventory transferred to property and equipment as demo devices | ​ | $ | 114 | ​ | $ | — | ​

​

The accompanying notes are an integral part of these condensed consolidated financial statements.

​

5

​

Table of Contents

ZYNEX, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(AMOUNTS IN THOUSANDS, EXCEPT SHARE DATA)

(unaudited)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Additional | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Total
​ | ​ | Common Stock | ​ | Paid-in | ​ | Treasury | ​ | Retained | ​ | Non-Controlling | ​ | Stockholders’
​ |  | Shares |  | Amount |  | Capital |  | Stock |  | Earnings |  | Interest |  | Equity
Balance, December 31, 2019 | ​ | 32,791,665 | ​ | $ | 34 | ​ | $ | 9,198 | ​ | $ | (3,846) | ​ | $ | 14,356 | ​ | $ | (89) | ​ | $ | 19,653
Exercised and vested stock-based awards | ​ | 385,917 | ​ |  | — | ​ |  | 221 | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | 221
Stock-based compensation expense | ​ | — | ​ |  | — | ​ |  | 497 | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | 497
Net income | ​ | — | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | 2,937 | ​ |  | — | ​ |  | 2,937
Balance at March 31, 2020 | ​ | 33,177,582 | ​ | $ | 34 | ​ | $ | 9,916 | ​ | $ | (3,846) | ​ | $ | 17,293 | ​ | $ | (89) | ​ | $ | 23,308
Exercised and vested stock-based awards, net of tax | ​ | 157,414 | ​ |  | — | ​ |  | 53 | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | 53
Stock-based compensation expense | ​ | — | ​ |  | — | ​ |  | 579 | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | 579
Net income | ​ | — | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | 3,017 | ​ |  | — | ​ |  | 3,017
Balance at June 30, 2020 | ​ | 33,334,996 | ​ | ​ | 34 | ​ | ​ | 10,548 | ​ | ​ | (3,846) | ​ | ​ | 20,310 | ​ | ​ | (89) | ​ | ​ | 26,957

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Additional | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Total
​ | ​ | Common Stock | ​ | Paid-in | ​ | Treasury | ​ | Retained | ​ | Non-Controlling | ​ | Stockholders’
​ |  | Shares |  | Amount |  | Capital |  | Stock |  | Earnings |  | Interest |  | Equity
Balance, December 31, 2020 | ​ | 34,791,931 | ​ | $ | 36 | ​ | $ | 37,235 | ​ | $ | (3,846) | ​ | $ | 23,430 | ​ | $ | — | ​ | $ | 56,855
Exercised and vested stock-based awards | ​ | 57,769 | ​ | ​ | 1 | ​ | ​ | 29 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 30
Stock-based compensation expense | ​ | — | ​ |  | — | ​ |  | 108 | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | 108
Shares of common stock withheld to pay taxes on employees' equity awards | ​ | (3,758) | ​ | ​ | — | ​ | ​ | (59) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (59)
Warrants exercised | ​ | 8,848 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | —
Treasury stock | ​ | (5,000) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (75) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (75)
Net income | ​ | — | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | (706) | ​ |  | — | ​ |  | (706)
Balance at March 31, 2021 | ​ | 34,849,790 | ​ | $ | 37 | ​ | $ | 37,313 | ​ | $ | (3,921) | ​ | $ | 22,724 | ​ | $ | — | ​ | $ | 56,153
Exercised and vested stock-based awards, net of tax | ​ | 85,190 | ​ | ​ | — | ​ | ​ | 59 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 59
Stock-based compensation expense | ​ | — | ​ | ​ | — | ​ | ​ | 401 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 401
Shares of common stock withheld to pay taxes on employees' equity awards | ​ | (31,902) | ​ | ​ | — | ​ | ​ | (76) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (76)
Treasury stock | ​ | (135,179) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (2,045) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (2,045)
Net income | ​ | — |  | ​ | — |  | ​ | — |  | ​ | — |  | ​ | 2,808 |  | ​ | — |  | ​ | 2,808
Balance at June 30, 2021 | ​ | 34,767,899 | ​ | $ | 37 | ​ | $ | 37,697 | ​ | $ | (5,966) | ​ | $ | 25,532 | ​ | $ | — | ​ | $ | 57,300

​

​

​

6

​

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

(1) BASIS OF PRESENTATION

Organization

Zynex, Inc. (a Nevada corporation) has its headquarters in Englewood, Colorado. The term “the Company” refers to Zynex, Inc. and its active and inactive subsidiaries. The Company operates in one primary business segment, medical devices which include electrotherapy and pain management products. As of June 30, 2021, the Company’s only active subsidiary is Zynex Medical, Inc. (“ZMI,” a wholly-owned Colorado corporation) through which the Company conducts most of its operations. Zynex Monitoring Solutions, Inc. (“ZMS,” a wholly-owned Colorado corporation) has developed a blood volume monitoring device which received approval by the U.S. Food and Drug Administration (“FDA”) during 2020 and is still awaiting CE Marking in Europe. ZMS has achieved no revenues to date. The Company’s inactive subsidiaries include Zynex Europe, Zynex NeuroDiagnostics, Inc. (“ZND,” a wholly-owned Colorado corporation) and Pharmazy, Inc. (“Pharmazy”), which was incorporated in June 2015 as a wholly-owned Colorado corporation. The Company’s compounding pharmacy operated as a division of ZMI dba as Pharmazy through January 2016.

Nature of Business

The Company designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The Company’s devices are intended for pain management to reduce reliance on drugs and medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current (“IFC”), neuromuscular electrical stimulation (“NMES”) and transcutaneous electrical nerve stimulation (“TENS”). All our medical devices are designed to be patient friendly and designed for home use. Our devices are small, portable, battery operated and include an electrical pulse generator which is connected to the body via electrodes. All of our medical devices are marketed in the U.S. and are subject to FDA regulation and approval. Our products require a physician’s prescription before they can be dispensed in the U.S. Our primary product is the NexWave device. The NexWave is marketed to physicians and therapists by our field sales representatives. The NexWave requires consumable supplies, such as electrodes and batteries, which are shipped to patients on a recurring monthly basis, as needed.

During the three and six months ended June 30, 2021 and 2020, the Company generated all of its revenue in North America from sales of its devices and supplies to patients and health care providers.

Unaudited Consolidated Financial Statements

The unaudited consolidated financial statements included herein have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and accounting principles generally accepted in the United States of America (“U.S. GAAP”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures included herein are adequate to make the information presented not misleading. A description of the Company’s accounting policies and other financial information is included in the audited consolidated financial statements as filed with the SEC in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. Amounts as of December 31, 2020, are derived from those audited consolidated financial statements. These interim consolidated financial statements should be read in conjunction with the annual audited financial statements, accounting policies and notes thereto, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

In the opinion of management, the accompanying unaudited consolidated financial statements contain all adjustments necessary to present fairly the financial position of the Company as of June 30, 2021 and the results of its operations and its cash flows for the periods presented. The results of operations for the three and six months ended June 30, 2021 are not necessarily indicative of the results that may be achieved for a full fiscal year and cannot be used to indicate financial performance for the entire year.

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Zynex, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

7

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

Reclassifications

During 2020, the Company revised its cost center allocations to better align with its business operations. As a result, reclassifications between general and administrative and selling and marketing expenses have been made to the three and six months ended June 30, 2020 financial statements to conform to the consolidated 2021 financial statement presentation. These reclassifications had no effect on net earnings, retained earnings or cash flows as previously reported.

Use of Estimates

Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The most significant management estimates used in the preparation of the accompanying consolidated financial statements are associated with the allowance for billing adjustments and uncollectible accounts receivable, the reserve for obsolete and damaged inventory, stock-based compensation, and valuation of long-lived assets and realizability of deferred tax assets.

Leases

The Company determines if an arrangement is a lease at inception or modification of a contract.

The Company recognizes finance and operating lease right-of-use assets and liabilities at the lease commencement date based on the estimated present value of the remaining lease payments over the lease term. For our finance leases, the Company uses the implicit rate to determine the present value of future lease payments. For our operating leases that do not provide an implicit rate, the Company uses incremental borrowing rates to determine the present value of future lease payments. The Company includes options to extend or terminate a lease in the lease term when it is reasonably certain to exercise such options. The Company recognizes leases with an initial term of 12 months or less as lease expense over the lease term and those leases are not recorded on our Consolidated Balance Sheets. For additional information on our leases where the Company is the lessee, see Note 7- Leases.

A significant portion of our device revenue is derived from patients who obtain our devices under month-to-month lease arrangements where the Company is the lessor. Revenue related to devices on lease is recognized in accordance with ASC 842, Leases. Using the guidance in ASC 842, we concluded our transactions should be accounted for as operating leases based on the following criteria below:

| ● | The lease does not transfer ownership of the underlying asset to the lessee by the end of the lease term.

| ● | The lease does not grant the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise.

| ● | The lease term is month-to-month, which does not meet the major part of the remaining economic life of the underlying asset. However, if the commencement date falls at or near the end of the economic life of the underlying asset, this criterion shall not be used for purposes of classifying the lease.

| ● | There is no residual value guaranteed and the present value of the sum of the lease payments does not equal or exceed substantially all of the fair value of the underlying asset.

| ● | The underlying asset is expected to have alternative uses to the lessor at the end of the lease term.

Lease commencement occurs upon delivery of the device to the patient. The Company retains title to the leased device and those devices are classified as property and equipment on the balance sheet. Since our leases are month-to-month and can be returned by the patient at any time, revenue is recognized monthly for the duration of the period in which the patient retains the device.

8

​

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

Accounts Receivable, Net

The Company’s accounts receivables represent unconditional rights to consideration and are generated when a patient receives one of the Company’s devices, related supplies or complimentary products. In conjunction with fulfilling the Company’s obligation to deliver a product, the Company invoices the patient’s third-party payor or the patient. Billing adjustments represent the difference between the list price and the reimbursement rates set by third-party payors, including Medicare, commercial payors and amounts billed directly to the patient. Specific amounts, if uncollected over a period of time, may be written-off after several appeals, which in some cases may take longer than twelve months. Substantially all of the Company’s receivables are due from patients with commercial or government health plans and workers compensation claims with a small portion related to private pay individuals, attorney and auto claims.

Revenue Recognition

Revenue is derived from sales and leases of our electrotherapy devices and sales of related supplies and complimentary products. The Company recognizes revenue when control of the product has been transferred to the patient, in the amount that reflects the consideration the Company expects to receive. In general, revenue from sales of our devices and supplies is recognized once the product is delivered to the patient, which is when control is deemed to have transferred to our patient.

Sales of our devices and supplies are primarily made with and shipped directly to the patient with a small amount of revenue generated from sales to distributors. In the healthcare industry there is often a third party involved that will pay on the patients’ behalf for purchased or leased devices and supplies. The terms of the separate arrangement impact certain aspects of the contracts, with patients covered by third party payors, such as contract type, performance obligations and transaction price, but for purposes of revenue recognition the contract with the customer refers to the arrangement between the Company and the patient. The Company does not have any material deferred revenue in the normal course of business as each performance obligation is met upon delivery of goods to the patient. There are no substantial costs incurred through support or warranty obligations.

The following table provides a breakdown of net revenue related to devices accounted for as purchases subject to ASC 606 and leases subject to ASC 842 (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the Three Months Ended June 30, | ​ | For the Six Months Ended June 30,
​ |  | 2021 |  | 2020 |  | 2021 |  | 2020
Device revenue |  | ​ |  |  | ​ |  | ​ | ​ |  |  | ​ |
Purchased | ​ | $ | 2,337 | ​ | $ | 1,223 | ​ | $ | 4,668 | ​ | $ | 2,503
Leased | ​ |  | 5,491 | ​ |  | 3,058 | ​ |  | 9,525 | ​ |  | 5,222
Total Device revenue | ​ | $ | 7,828 | ​ | $ | 4,281 | ​ | $ | 14,193 | ​ | $ | 7,725

​

Revenues are estimated using the portfolio approach by third-party payor type based upon historical rates of collection, aging of receivables, trends in historical reimbursement rates by third-party payor types, and current relationships and experience with the third-party payors, which includes estimated constraints for third-party payor refund requests, deductions and adjustments. Inherent in these estimates is the risk that they will have to be revised as additional information becomes available and constraints are released. Specifically, the complexity of third-party payor billing arrangements and the uncertainty of reimbursement amounts for certain products from third-party payors or unanticipated requirements to refund payments previously received may result in adjustments to amounts originally recorded. Due to continuing changes in the health care industry and third-party payor reimbursement, it is possible our forecasting model to estimate collections could change, which could have an impact on our results of operations and cash flows. Any differences between estimated and actual collectability are reflected in the period in which the difference is identified. Historically these differences have been immaterial and the Company has not had a significant reversal of revenue from prior periods.

9

​

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

A change in the way estimates are determined can result from a number of factors, including changes in the reimbursement policies or practices of third-party payors, or changes in industry rates of reimbursement. The Company monitors the variability and uncertain timing over third-party payor types in our portfolios. If there is a change in our third-party payor mix over time, it could affect our net revenue and related receivables. We believe we have a sufficient history of collection experience to estimate the net collectible amounts by third-party payor type. However, changes to constraints for billing adjustments have historically fluctuated and may continue to fluctuate significantly from quarter to quarter and year to year.

Stock-based Compensation

The Company accounts for stock-based compensation through recognition of the cost of employee services received in exchange for an award of equity instruments, which is measured based on the grant date fair value of the award that is ultimately expected to vest during the period. The stock-based compensation expenses are recognized over the period during which an employee is required to provide service in exchange for the award (the requisite service period, which in the Company’s case is the same as the vesting period). For awards subject to the achievement of performance metrics, stock-based compensation expense is recognized when it becomes probable that the performance conditions will be achieved over the respective performance period.

Fair Value of Financial Instruments

The Company’s financial instruments include cash, accounts receivable, accounts payable, and accrued liabilities, for which current carrying amounts approximate fair value due to their short-term nature. Financial instruments also include our operating and finance lease obligations, the carrying value of which approximates fair value because the interest rates on the outstanding borrowings are at rates that approximate market rates for borrowings with similar terms and average maturities.

Inventory, Net

Inventories are stated at the lower of cost and net realizable value. Cost is computed using standard costs, which approximates actual costs on an average cost basis. Following are the components of inventory (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | June 30, 2021 |  | December 31, 2020
Raw Materials | ​ | $ | 4,163 | ​ | $ | 3,213
Work-in-process | ​ |  | 686 | ​ |  | 1,455
Finished Goods | ​ |  | 5,254 | ​ |  | 4,119
​ | ​ | $ | 10,103 | ​ | $ | 8,787
Less: reserve | ​ |  | (152) | ​ |  | (152)
​ | ​ | $ | 9,951 | ​ | $ | 8,635

​

The Company monitors inventory for turnover and obsolescence and records losses for excess and obsolete inventory, as appropriate. The Company provides reserves for estimated excess and obsolete inventories based upon assumptions about future demand. If future demand is less favorable than currently projected by management, additional inventory write-downs may be required.

Segment Information

We define operating segments as components of our enterprise for which separate financial information is reviewed regularly by the chief operating decision-makers to evaluate performance and to make operating decisions. We have identified our Chief Executive Officer, Chief Financial Officer, and Chief Operating Officer as our chief operating decision-makers (“CODM”).

We currently operate our business as one operating segment which includes two revenue types: Devices and Supplies.

10

​

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

Income Taxes

We record deferred tax assets and liabilities for the estimated future tax effects of temporary differences between the tax bases of assets and liabilities and amounts reported in the accompanying consolidated balance sheets, as well as operating loss and tax credit carry-forwards. We measure deferred tax assets and liabilities using enacted tax rates expected to be applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. We reduce deferred tax assets by a valuation allowance if, based on available evidence, it is more likely than not that these benefits will not be realized.

We recognize tax benefits from uncertain tax positions if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position.

Recent Accounting Pronouncements

In June 2016, FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326) ("ASU 2016-13"), Measurement of Credit Losses on Financial Instruments. The standard significantly changes how entities will measure credit losses for most financial assets and certain other instruments that aren't measured at fair value through net income. The standard will replace today's "incurred loss" approach with an "expected loss" model for instruments measured at amortized cost. For available-for-sale debt securities, entities will be required to record allowances rather than reduce the carrying amount, as they do today under the other-than-temporary impairment model. It also simplifies the accounting model for purchased credit-impaired debt securities and loans. This ASU is effective for annual periods beginning after December 15, 2022, and interim periods therein for smaller reporting companies. Early adoption is permitted for annual periods beginning after December 15, 2018, and interim periods therein. The Company is currently evaluating the impact that the adoption of ASU 2016-13 will have on our financial condition, results of operations and cash flows.

Management has evaluated other recently issued accounting pronouncements and does not believe that any of these pronouncements will have a material impact on the Company’s consolidated financial statements.

​

​

(2) PROPERTY AND EQUIPMENT

The components of property and equipment are as follows (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | June 30, 2021 |  | December 31, 2020
Property and equipment | ​ | ​ |  |  | ​ |
Office furniture and equipment | ​ | $ | 2,252 | ​ | $ | 2,362
Assembly equipment | ​ |  | 151 | ​ |  | 143
Vehicles | ​ |  | 198 | ​ |  | 198
Leasehold improvements | ​ |  | 1,013 | ​ |  | 559
Sales Rep demo units | ​ | ​ | 215 | ​ | ​ | 361
Leased devices | ​ |  | 1,351 | ​ |  | 809
​ | ​ | ​ | 5,180 | ​ | ​ | 4,432
Less accumulated depreciation | ​ |  | (2,825) | ​ |  | (2,507)
​ | ​ | $ | 2,355 | ​ | $ | 1,925

​

Total depreciation expense related to our property and equipment was $0.2 million and $0.1 million for the three months ended June 30, 2021 and 2020, respectively. Depreciation expense for the six-month periods ended June 30, 2021 and 2020 was $0.3 million and $0.2 million, respectively.

Total depreciation expense related to devices out on lease was $0.4 million and $0.2 million for the three months ended June 30, 2021 and 2020, respectively. Depreciation expense related to devices out on lease was $0.6 million and $0.4 million for the six months ended June 30, 2021 and 2020, respectively. Depreciation on leased units is reflected on the income statement as cost of revenue.

11

​

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

Total depreciation expense related to demo unit devices out with sales representatives was $0.1 million and nil for the three months ended June 30, 2021 and 2020, respectively. Total depreciation expense related to demo unit devices out with sales representatives was $0.2 million and nil for the six months ended June 30, 2021 and 2020, respectively. Deprecation on demo units is reflected on the income statement as sales and marketing expense.

The Company monitors devices out on lease for potential loss and places an estimated reserve on the net book value based on an analysis of the number of units which are still with patients for which the Company cannot determine the current status.

The Company monitors demo devices for potential losses and places an estimated reserve on the net book value based on an analysis of terminated territory managers that have not yet returned their units.

​

(3) EARNINGS PER SHARE

Basic earnings per share are computed by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income by the weighted-average number of common shares outstanding and the number of dilutive potential common share equivalents during the period, calculated using the treasury-stock method for outstanding stock options. In periods of losses, diluted loss per share is computed on the same basis as basic loss per share as the inclusion of any other potential common shares outstanding would be anti-dilutive.

The calculation of basic and diluted earnings per share for the three and six months ended June 30, 2021 and 2020 are as follows (in thousands, except per share data):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the Three Months Ended June 30, | ​ | For the Six Months Ended June 30, | ​
​ |  | 2021 |  | 2020 |  | 2021 |  | 2020 | ​
Basic earnings per share |  | ​ |  |  | ​ |  |  | ​ |  |  | ​ |  | ​
Net income available to common stockholders | ​ | $ | 2,808 | ​ | $ | 3,017 | ​ | $ | 2,102 | ​ | $ | 5,954 | ​
Basic weighted-average shares outstanding | ​ |  | 34,810 | ​ |  | 33,283 | ​ |  | 34,824 | ​ |  | 33,098 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Basic earnings per share | ​ | $ | 0.08 | ​ | $ | 0.09 | ​ | $ | 0.06 | ​ | $ | 0.18 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Diluted earnings per share | ​ |  |  | ​ |  |  | ​ |  |  | ​ |  |  | ​
Net income available to common stockholders | ​ | $ | 2,808 | ​ | $ | 3,017 | ​ | $ | 2,102 | ​ | $ | 5,954 | ​
Weighted-average shares outstanding | ​ |  | 34,810 | ​ |  | 33,283 | ​ |  | 34,824 | ​ |  | 33,098 | ​
Effect of dilutive securities - options and restricted stock | ​ |  | 773 | ​ |  | 1,171 | ​ |  | 805 | ​ |  | 1,231 | ​
Diluted weighted-average shares outstanding | ​ |  | 35,583 | ​ |  | 34,454 | ​ |  | 35,629 | ​ |  | 34,329 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Diluted earnings per share | ​ | $ | 0.08 | ​ | $ | 0.09 | ​ | $ | 0.06 | ​ | $ | 0.17 | ​

​

For the three and six months ended June 30, 2021, options to purchase 0.1 million and 0.2 million shares, respectively, of common stock were excluded from the dilutive stock calculation because their effect would have been anti-dilutive.

​

For the three and six months ended June 30, 2020, options to purchase 14,000 and 59,000 shares, respectively, of common stock were excluded from the dilutive stock calculation because their effect would have been anti-dilutive.

​

(4) STOCK-BASED COMPENSATION PLANS

In June 2017, our stockholders approved the 2017 Stock Incentive Plan (the “2017 Stock Plan”) with a maximum of 5,000,000 shares reserved for issuance. Awards permitted under the 2017 Stock Plan include: Stock Options and Restricted Stock. Awards issued under the 2017 Stock Plan are at the discretion of the Board of Directors. As applicable, awards are granted with an exercise price equal to the closing price of our common stock on the date of grant and generally vest over four years. Restricted Stock Awards are issued to the recipient upon grant and are not included in outstanding shares until such vesting and issuance occurs.

12

​

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

During the three and six months ended June 30, 2021, no stock option awards were granted under the 2017 Stock Plan. During the three months ended June 30, 2020, no stock option awards were granted under the 2017 Stock Plan. During the six months ended June 30, 2020, 14,000 stock option awards were granted under the 2017 Stock Plan. At June 30, 2021, the company had 0.7 million stock options outstanding and 0.6 million exercisable under the following plans:

​

​ | ​ | ​ | ​ | ​ | ​
​ |  | Outstanding |  | Exercisable
​ | ​ | Number of Options | ​ | Number of Options
​ | ​ | (in thousands) | ​ | (in thousands)
Plan Category |  |  |  | ​ |
2005 Stock Option Plan |  | 295 |  | ​ | 295
Equity Compensation Plans not approved by Shareholders |  | 37 |  | ​ | 37
2017 Stock Option Plan |  | 412 |  | ​ | 265
Total |  | 744 | ​ | ​ | 597

​

During the three and six months ended June 30, 2021, 30,000 and 95,000 shares of restricted stock were granted to the Board of Directors and management under the 2017 Stock Plan, respectively. During the three and six months ended June 30, 2020, 38,000 and 208,000 shares of restricted stock were granted to the Board of Directors and management under the 2017 Stock Plan, respectively. The fair market value of restricted shares for share-based compensation expensing is equal to the closing price of our common stock on the date of grant. The vesting on the Restricted Stock Awards typically occur quarterly over three years for the Board of Directors and quarterly or annually over two to four years for management.

​

The following summarizes stock-based compensation expenses recorded in the consolidated statements of operations (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the Three Months Ended June 30, |  | For the Six Months Ended June 30, | ​
​ |  | 2021 |  | 2020 |  | 2021 |  | 2020 | ​
Cost of Revenue | ​ | $ | 15 | ​ | $ | 2 | ​ | $ | 30 | ​ | $ | 9 | ​
Sales and marketing expense | ​ |  | 15 | ​ |  | 98 | ​ |  | 30 | ​ |  | 127 | ​
General, and administrative | ​ | ​ | 371 | ​ | ​ | 479 | ​ | ​ | 449 | ​ | ​ | 940 | ​
Total stock based compensation expense | ​ | ​ | 401 | ​ | ​ | 579 | ​ | ​ | 509 | ​ | ​ | 1,076 | ​

​

The Company received proceeds of $0.1 million related to option exercises during each of the three and six months ended June 30, 2021, respectively. The Company received proceeds of $0.1 million and $0.3 million related to option exercises during the three and six months ended June 30, 2020, respectively.

The Company did not grant any stock options during the three and six months ended June 30, 2021, nor during the three months ended June 30, 2020. The Company used the Black Scholes option pricing model to determine the fair value of stock option grants, using the following assumptions for the six months ended June 30, 2020:

​

​ | ​ | ​ | ​
Expected term (years) | ​ | 6.79 | ​
Risk-free interest rate | ​ | 1.59 | %
Expected volatility | ​ | 116.76 | %
Expected dividend yield | ​ | — | %

​

13

​

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

A summary of stock option activity under all equity compensation plans for the six months ended June 30, 2021, is presented below:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Weighted- | ​ | ​ | ​
​ | ​ | ​ | ​ | Weighted- | ​ | Average | ​ | Aggregate
​ | ​ | Number of | ​ | Average | ​ | Remaining | ​ | Intrinsic
​ | ​ | Shares | ​ | Exercise | ​ | Contractual | ​ | Value
​ |  | (in thousands) |  | Price |  | Term (Years) |  | (in thousands)
Outstanding at December 31, 2020 |  | 1,006 | ​ | $ | 3.04 | ​ | 6.47 | ​ | $ | 10,483
Forfeited |  | (190) | ​ | $ | 7.34 | ​ | ​ | ​ |  | ​
Exercised | ​ | (72) | ​ | $ | 6.90 | ​ | ​ | ​ | ​ | ​
Outstanding at June 30, 2021 |  | 744 | ​ | $ | 1.57 | ​ | 5.29 | ​ | $ | 10,386
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Exercisable at June 30, 2021 |  | 597 | ​ | $ | 1.01 | ​ | 4.78 | ​ | $ | 8,674

​

A summary of restricted stock award activity under all equity compensation plans for the six months ended June 30, 2021, is presented below:

​

​ | ​ | ​
​ | ​ | Number of
​ | ​ | Shares
​ |  | (in thousands)
Granted but not vested at December 31, 2020 |  | 268
Granted |  | 95
Forfeited |  | (68)
Vested |  | (71)
Granted but not vested at June 30, 2021 |  | 224

​

As of June 30, 2021, the Company had approximately $3.4 million of unrecognized compensation expense related to stock options and restricted stock awards that will be recognized over a weighted average period of approximately 2.4 years.

​

(5) STOCKHOLDERS’ EQUITY

Treasury Stock

On March 8, 2021, our Board of Directors approved a program to repurchase up to $10.0 million of our common stock at prevailing market prices either in the open market or through privately negotiated transactions through September 8, 2021. From the inception of the plan through June 30, 2021, the Company purchased 140,179 shares of our common stock for $2.1 million or an average price of $15.12 per share.

Warrants

A summary of stock warrant activity for the six months ended June 30, 2021 is presented below:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Weighted | ​ | ​ | ​
​ | ​ | ​ | ​ | Weighted | ​ | Average | ​ | Aggregate
​ | ​ | Number of | ​ | Average | ​ | Remaining | ​ | Intrinsic
​ | ​ | Warrants | ​ | Exercise | ​ | Contractual | ​ | Value
​ |  | (in thousands) |  | Price |  | Life (Years) |  | (in thousands)
Outstanding at December 31, 2020 |  | 100 | ​ | $ | 2.63 | ​ |  | 3.76 | ​ | $ | 1,084
Granted |  | — | ​ | $ | — | ​ |  | ​ | ​ | ​ | ​
Exercised |  | (10) | ​ | $ | 2.50 | ​ |  | 3.27 | ​ |  | 192
Forfeited |  | — | ​ | $ | — | ​ |  | ​ | ​ |  | ​
Outstanding and Exercisable at June 30, 2021 |  | 90 | ​ | $ | 2.64 | ​ |  | 3.27 | ​ | $ | 1,160

​

​

​

14

​

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

(6) INCOME TAXES

The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, primarily related to excess tax benefits on stock option exercises. For the three and six months ended June 30, 2021 discrete items adjusted were $0.1 million and $0.5 million, respectively. At June 30, 2021 the Company is currently estimating an annual effective tax rate of approximately 26%. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to various factors.

The provision for income taxes is recorded at the end of each interim period based on the Company’s best estimate of its effective income tax rate expected to be applicable for the full fiscal year. The Company’s effective income tax rate was 22% for the six months ended June 30, 2021. The Company recorded income tax expense of $1.0 million and $0.6 million for the three and six months ended June 30, 2021, respectively, and income tax expense of $1.1 million and $0.6 million for the three and six months ended June 30, 2020.

Taxes of $0.3 million and $0.6 million were paid during the six months ended June 30, 2021 and 2020, respectively.

​

(7) LEASES

The Company has five operating leases; four pertaining to its corporate headquarters and one for its warehouse facility located in Englewood, CO. Details of each lease are as follows:

| ● | The Company entered into a sublease agreement on October 20, 2017 with CSG Systems Inc. for approximately 41,715 square feet. The term of the sublease runs through June 30, 2023, with an option to extend for an additional two years through June 30, 2025. During the first year of the sublease, the rent per square foot is $7.50, which increased to $19.75 during the second year of the sublease and each year thereafter increasing by an additional $1 per square foot. The Company has not yet determined whether it is reasonably certain to exercise its renewal option and has therefore only considered the initial term when determining the lease liability and lease asset. The Company is also obligated to pay its proportionate share of building operating expenses. The sub-landlord agreed to contribute approximately $0.2 million toward tenant improvements which was accounted for as a reduction of the operating lease asset and subsequently treated as a reduction of rent expense over the term of the lease. Upon lease commencement, the Company recorded an operating lease liability of $3.9 million and a corresponding right-of-use asset for $3.6 million. The remaining lease term was 2.0 years at June 30, 2021.

| ● | The Company entered into an amendment to its sublease agreement, above, on March 11, 2019 for an additional 21,420 square feet of office space. The term of the sublease for the additional space began on June 1, 2019 and runs through June 30, 2023, with an option to extend the term for an additional two years through June 30, 2025. During the first seven months of the Amendment to the Sublease, the rent per square foot was $10.00, which increased to $20.75 from January 1, 2020 through October 31, 2020. For annual periods beginning November 1, 2020, the price per square foot increases by an additional $1 per square foot. Upon lease commencement, the Company recorded an operating lease liability and a corresponding right-of-use asset for $1.6 million each. The remaining lease term was 2.0 years at June 30, 2021.

| ● | The Company entered into an amendment to its sublease agreement, above, on January 3, 2020 for an additional 22,546 square feet of office space. The term of the sublease began on March 9, 2020 and will run through June 30, 2025. From the commencement date through October 31, 2020, the rent per square foot is $13.00, increasing to $21.75 per square foot from November 1, 2020 through October 31, 2021. The price per square foot increases by an additional $1 annually beginning November 1, 2021. Upon lease commencement, the Company recorded an operating lease liability and a corresponding right-of-use asset for $1.4 million each. The remaining lease term was 2.0 years at June 30, 2021.

15

​

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

| ● | The Company entered into a lease agreement on September 17, 2020 with GIG CW Compark, LLC for approximately 50,488 square feet. The term of the lease began on January 5, 2021 and will run through June 5, 2026. The lease includes an option to extend the lease for one additional five year period. Base rent began at $9.40 per square feet increasing each year thereafter by an additional $0.30 per square foot. The Company has not yet determined whether or not it is reasonably certain to exercise its renewal option. The Company is also obligated to pay its proportional share of building operating expenses. The landlord agreed to contribute approximately $0.4 million toward tenant improvements. The Company determined that lease commencement occurred earlier than lease inception on January 5, 2021 as the Company began making significant tenant improvements and storing inventory at this location during December 2020. Upon lease commencement, the Company recorded an operating lease liability of $2.4 million and a corresponding right-of-use asset of $2.1 million. The remaining lease term was 5.1 years at June 30, 2021.

| ● | The Company entered into a sublease agreement on April 9, 2021 with Cognizant Trizetto Software Group, Inc. for up to approximately 110,754 square feet of office space as its new corporate headquarters. The term of the sublease began on May 1, 2021 and will run through April 29, 2028. The Company is entitled to rent credits equal to twenty-one months of base rent at the initial rate. During the first thirty-three months of the sublease, the rent per square foot is $26.50. The price per square foot increases by an additional $0.50 during each subsequent twelve-month period of the sublease. Upon lease commencement, the Company recorded an operating lease liability and a corresponding right-of-use asset for $13.4 million each. The remaining lease term was 6.9 years at June 30, 2021.

The Company has five finance leases for office equipment as follows:

| ● | The Company entered into an equipment lease on September 20, 2019 with Konica Minolta Premier Finance for a copier/printer and related software located at its corporate offices. The term of the equipment lease agreement is 5 years with the option to purchase the equipment at the end of the lease. The Company does not expect to exercise the option to purchase the equipment and, accordingly, has not considered the effect of the purchase in the evaluation of the lease asset and liability. Rent is to be paid monthly at a fixed rate for the term of the equipment lease agreement. Upon lease commencement, the Company recorded a finance lease liability and a corresponding right-of-use asset for $0.2 million each. The remaining lease term was 3.3 years at June 30, 2021.

| ● | The Company entered into an equipment lease on March 3, 2020 with Konica Minolta Premier Finance for copiers/printers and related software located at its corporate offices. The term of the equipment lease agreement is 4 years with the option to purchase the equipment at the end of the lease. The Company does not expect to exercise the option to purchase the equipment and, accordingly, has not considered the effect of the purchase in the evaluation of the lease asset and liability. Rent is to be paid monthly at a fixed rate for the term of the equipment lease agreement. Upon lease commencement, the Company recorded a finance lease liability and a corresponding right-of-use asset for $0.1 million each. The remaining lease term was 2.7 years at June 30, 2021.

| ● | The Company entered into an equipment lease on November 25, 2020 with Konica Minolta Premier Finance for copiers/printers and related software located at its Grasslands warehouse facility in Colorado. The term of the equipment lease is 5 years with the option to purchase the equipment at the end of the lease. The Company does not expect to exercise the option to purchase the equipment and, accordingly, has not considered the effect of the purchase in the evaluation of the lease asset and liability. Rent is to be paid monthly at a fixed rate for the term of the equipment lease agreement. Upon lease commencement, the Company recorded a finance lease liability and a corresponding right-of-use asset for $0.1 million each. The remaining lease term was 4.5 years at June 30, 2021.

| · | The Company entered into an equipment lease on December 14, 2020 with Konica Minolta Premier Finance for mail solution and related software located at its Grasslands warehouse facility in Colorado. The term of the equipment lease is 5.3 years with the option to purchase the equipment at the end of the lease. The Company does not expect to exercise the option to purchase the equipment and, accordingly, has not considered the effect of the purchase in the evaluation of the lease asset and liability. Rent is to be paid monthly at a fixed rate for the term of the equipment lease agreement. Upon lease commencement, the Company recorded a finance lease liability and a corresponding right-of-use asset for $0.2 million each. The remaining lease term was 5.1 years at June 30, 2021.

16

​

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

| ● | The Company entered into an equipment lease on November 3, 2020 with Altitude Leasing for a baler located at its Grasslands warehouse facility in Colorado. The term of the equipment lease is 3 years with no option to purchase the equipment at the end of the lease. Rent is to be paid monthly at a fixed rate for the term of the equipment lease agreement. Upon lease commencement, the Company recorded a finance lease liability and a corresponding right-of-use asset for $8,000 each. The remaining lease term was 2.5 years at June 30, 2021.

The Company’s operating leases do not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring the lease liability. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. The Company’s incremental borrowing rate was determined to be 4.0% for its operating lease liabilities. The Company’s equipment lease agreements have implicit rates from 8.3% to 20.7%, which were used to measure its finance lease liability.

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Operating lease liability | ​ | Finance lease liability
​ |  | (in thousands) |  | (in thousands)
July 1, 2021 through December 31, 2021 | ​ | $ | 1,183 | ​ | $ | 73
2022 |  | ​ | 3,570 |  | ​ | 147
2023 |  | ​ | 2,981 |  | ​ | 147
2024 |  | ​ | 3,496 |  | ​ | 114
2025 |  | ​ | 3,567 |  | ​ | 73
2026 and thereafter | ​ | ​ | 7,532 | ​ | ​ | 19
Total undiscounted future minimum lease payments |  | $ | 22,329 |  | $ | 573
Less: Difference between undiscounted lease payments and discounted lease liabilities: |  | ​ | (2,826) |  | ​ | (96)
Total lease liabilities | ​ | $ | 19,503 | ​ | $ | 477

​

Operating lease costs were $0.9 million and $1.5 million for the three and six months ended June 30, 2021, respectively. Operating lease costs were $0.4 million and $0.8 million for the three and six months ended June 30, 2020, respectively. For the three and six months ended June 30, 2021, $0.2 million and $0.3 million, respectively, of operating lease costs incurred primarily at our manufacturing and warehouse facility were included in cost of sales and $0.7 million and $1.2 million, respectively, were included in general and administrative expenses on the consolidated statement of operations. All operating lease costs for the three and six months ended June 30, 2020 were included in general and administrative expenses on the consolidated statement of operations.

​

(8) CONCENTRATIONS

For the three months ended June 30, 2021, the Company sourced approximately 31% of the supplies for its electrotherapy products from one significant vendor (defined as supplying at least 10%). For the same period in 2020, the Company sourced approximately 36% of the supplies from one significant vendor.

For the six months ended June 30, 2021, the Company sourced approximately 35% of supplies for its electrotherapy products from two significant vendors. For the same period in 2020 the company sourced approximately 34% of supplies from one significant vendor.

Management believes that its relationships with suppliers are good; however, if the relationships were to be replaced, there may be a short-term disruption to operations, a period of time in which products may not be available and additional expenses may be incurred.

The Company had receivables from two third-party payers at June 30, 2021 that made up approximately 37% of the net accounts receivable balance. At December 31, 2020, the Company had receivables from one third-party payer that made up approximately 26% of the net accounts receivable balance.

​

17

​

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

(9) LITIGATION

From time to time, the Company may become party to litigation and other claims in the ordinary course of business. To the extent that such claims and litigation arise, management would accrue the estimated exposure for such events when losses are determined to be both probable and estimable.

The Company is currently not a party to any material pending legal proceedings.

​

​

​

18

​

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

​

Cautionary Notice Regarding Forward-Looking Statements

​

This quarterly report contains statements that are forward-looking, such as statements relating to plans for future organic growth and other business development activities, as well as the impact of reimbursement trends, other capital spending and financing sources. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, such results may differ from those expressed in any forward-looking statements made by or on behalf of the Company. These risks include the ability to engage effective sales representatives, the need to obtain U.S. Food and Drug Administration (“FDA”) clearance and Certificate European (“CE”) marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, our dependence on the reimbursement from third-party payors for products sold or leased to our patients, acceptance of our products by health third-party payors for reimbursement, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on third-party manufacturers to produce key components of our products on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the impact of COVID-19 on our business, and other risks described herein and in our Annual Report on Form 10-K for the year ended December 31, 2020.

​

These interim financial statements and the information contained in this Quarterly Report on Form 10-Q should be read in conjunction with the annual audited consolidated financial statements, and notes to consolidated financial statements, included in the Company’s 2020 Annual Report on Form 10-K and subsequently filed reports, which have previously been filed with the Securities and Exchange Commission.

​

General

​

Zynex, Inc. (a Nevada corporation) has its headquarters in Englewood, Colorado. We operate one primary business segment: medical devices which include electrotherapy and pain management products. As of June 30, 2021, the Company’s only active subsidiary is Zynex Medical, Inc. (“ZMI,” a wholly-owned Colorado corporation) through which the Company conducts most of its operations. One other subsidiary, Zynex Europe, ApS (“ZEU,” a wholly-owned Denmark corporation), did not generate material revenues during the three or six months ended June 30, 2021 and 2020 from international sales and marketing. Zynex Monitoring Solutions, Inc. (“ZMS,” a wholly-owned Colorado corporation) has developed a blood volume monitoring device, which was approved by the U.S. Food and Drug Administration (“FDA”) in February 2020 and is awaiting CE Marking approval in Europe. ZMS has achieved no revenues to date.

​

RESULTS OF OPERATIONS

​

Summary

​

Net revenue was $31.0 million and $19.3 million for the three months ended June 30, 2021 and 2020, respectively, and $55.1 million and $34.5 million for the six months ended June 30, 2021 and 2020, respectively. Net revenue increased 61% and 60% for the three and six-month periods ended June 30, 2021, respectively. Net income was $2.8 million for the three months ended June 30, 2021 compared with $3.0 million during the same period in 2020. Net income was $2.1 million for the six months ended June 30, 2021 compared with $6.0 million during the same period in 2020. Cash used in operating activities was $4.3 million during the six months ended June 30, 2021. Working capital at June 30, 2021 and December 31, 2020 was $52.9 million.

​

Net Revenue

​

Net revenues are comprised of device and supplies sales, constrained by estimated third-party payor reimbursement deductions and estimated uncollectible amounts. Product device revenue is primarily comprised of sales and rentals of our electrotherapy products and other complimentary products.

​

Supplies revenue is primarily comprised of sales of our consumable supplies to patients using our electrotherapy products, consisting primarily of surface electrodes and batteries.

​

19

Table of Contents

Revenue related to both devices and supplies is reported net, after adjustments for estimated third-party payor reimbursement deductions and estimated uncollectible amounts. Estimates for third-party payor reimbursement deductions and uncollectible accounts are adjusted on an ongoing basis in conjunction with the processing of third-party payor insurance claims and other customer collection history. Billing allowance adjustments are common in our industry whereby third-party payors unilaterally reduce the amount they reimburse for our products as compared to the sales price charged by us. These deductions from gross revenue take into account the estimated denials, net of resubmitted billings of claims for products placed with patients which may affect collectability. See our Significant Accounting Policies in Note 1 to the Consolidated Financial Statements for a more complete explanation of our revenue recognition policies.

​

We occasionally receive, and expect to continue to receive, refund requests from insurance providers relating to specific patients and dates of service. Billing and reimbursement disputes are very common in our industry. These requests are sometimes related to a few patients and other times include a significant number of refund claims in a single request. We review and evaluate these requests and determine if any refund is appropriate. We also review claims that have been resubmitted or where we are pursuing additional reimbursement from that insurance provider. We frequently have significant offsets against such refund requests which may result in amounts that are due to us in excess of the amounts of refunds requested by the insurance providers. Therefore, at the time of receipt of such refund requests we are generally unable to determine if a refund request is valid.

​

Net revenue increased $11.7 million or 61% to $31.0 million for the three months ended June 30, 2021, from $19.3 million for the same period in 2020. Net revenue increased $20.6 million or 60% to $55.1 million for the six months ended June 30, 2021, from $34.5 million for the same period in 2020. For both the three and six-month periods ended June 30, 2021, the growth in net revenue from the same periods in 2020 is primarily related to a 247% and 186% growth in device orders, respectively, which resulted from an increased customer base and led to higher sales of consumable supplies.

​

Device Revenue

​

Device revenue is related to the sale or lease of our electrotherapy and complimentary products. Device revenue increased $3.5 million or 83% to $7.8 million for the three months ended June 30, 2021, from $4.3 million for the same period in 2020.

​

Device revenue increased $6.5 million or 84% to $14.2 million for the six months ended June 30, 2021, from $7.7 million for the same period in 2020.

​

The increase in device revenue is primarily related to increased orders which are attributable to the growth of our sales force.

​

Supplies Revenue

​

Supplies revenue is related to the sale of supplies, primarily electrodes and batteries, for our products. Supplies revenue increased $8.2 million or 55% to $23.2 million for the three months ended June 30, 2021, from $15.0 million for the same period in 2020.

​

Supplies revenue increased $14.2 million or 53% to $41.0 million for the six months ended June 30, 2021, from $26.8 million for the same period in 2020.

​

The increase in supplies revenue is primarily related to an increased customer base from increased device sales in 2020 and 2021.

​

Operating Expenses

​

Cost of Revenue – Devices and Supplies

​

Cost of Revenue – devices and supplies consist primarily of device and supply costs, facilities, operations labor and overhead, shipping and depreciation. Cost of revenue for the three months ended June 30, 2021 increased 79% to $7.3 million from $4.1 million for the same period in 2020. As a percentage of revenue, cost of revenue – devices and supplies increased to 23% for the three months ended June 30, 2021 from 21% for the same period in 2020.

​

20

​

Table of Contents

Cost of revenue for the six months ended June 30, 2021 increased 76% to $13.2 million from $7.5 million for the same period in 2020. As a percentage of revenue, cost of revenue – device and supply increased to 24% for the six months ended June 30, 2021 from 22% for the same period in 2020. The increase in cost of revenue is primarily due to an increase overhead costs related to our new manufacturing and warehouse facility and freight costs, as well as an increase of 76% in device orders from the six months ended June 30, 2020.

​

The increase as a percentage of revenue for both the three and six months ended June 30, 2021 is due to lower collections from certain commercial payors as well as an increase in overhead costs related to our new facilities.

​

Sales and Marketing Expense

​

Sales and marketing expenses primarily consist of employee related costs, including commissions and other direct costs associated with these personnel including travel expenses and marketing campaign and related expenses.

​

Sales and marketing expense for the three months ended June 30, 2021 increased 102% to $13.8 million from $6.8 million for the same period in 2020. Sales and marketing expense for the six months ended June 30, 2021 increased 123% to $27.6 million from $12.4 million for the same period in 2020. The increase in sales and marketing expense is primarily due to the expansion of our sales force and the related costs associated with increased headcount. As a percentage of revenue, sales and marketing expense increased to 44% and 50% for the three and six months ended June 30, 2021, respectively, from 35% and 36% for the same periods in 2020. The increase as a percentage of revenue is primarily due to the increase in aforementioned expenses, partially offset by the increase in revenue during the period.

​

General and Administrative Expense

​

General and administrative expenses primarily consist of employee-related costs, and other direct costs associated with these personnel including facilities and travel expenses and professional fees, depreciation and amortization. General and administrative expense for the three months ended June 30, 2021 increased 43% to $6.2 million from $4.3 million for the same period in 2020. The increase in general and administrative expense for the three months is primarily due to increased compensation and benefit expense related to headcount growth. As a percentage of revenue, general and administrative expense decreased to 20% for the three months ended June 30, 2021 from 22% for the same period in 2020. The decrease as a percentage of revenue is primarily due to the increase in revenue during the period, partially offset by costs associated with increased headcount from the prior year.

​

General and administrative expense for the six months ended June 30, 2021 increased 44% to $11.7 million from $8.1 million for the same period in 2020. The increase in general and administrative expense for the six months is primarily due to increased compensation and benefit expense related to headcount growth. and increases in rent and facilities expense as we expanded our corporate headquarters during March 2020 and May 2021. As a percentage of revenue, general and administrative expense decreased to 21% for the six months ended June 30, 2021 from 23% for the same period in 2020. The decrease as a percentage of revenue is primarily due to the increase in revenue during the period, partially offset by the aforementioned expenses.

​

Income Taxes

​

The provision for income taxes is recorded at the end of each interim period based on the Company’s best estimate of its effective income tax rate expected to be applicable for the full fiscal year. The Company’s effective income tax rate was 26% and 22% for the three and six months ended June 30, 2021, respectively. Discrete items, primarily related to excess tax benefits related to stock option exercises, of $0.1 million and $0.5 million for the three and six months ended June 30, 2021, respectively, are recognized as a benefit against income tax expense. For the three and six months ended June 30, 2021 the Company had an income tax expense of approximately $1.0 million and $0.6 million, respectively. The Company recorded income tax expense of $1.1 million and $0.6 million for the three and six months ended June 30, 2020.

​

21

​

Table of Contents

LIQUIDITY AND CAPITAL RESOURCES

​

We have historically financed operations through cash flows from operations, debt and equity transactions. At June 30, 2021, our principal source of liquidity was $32.3 million in cash and $18.3 million in accounts receivable.

​

Net cash used in operating activities for the six months ended June 30, 2021 was $4.3 million compared with net cash provided by operating activities of $3.3 million for the six months ended June 30, 2020. The increase in cash used in operating activities for the six months ended June 30, 2021 was primarily due to the significant increase in inventory in 2021 as well as an increase in receivables balances. The increase in inventory is related to our order growth plus increased stockpiles in anticipation of possible supply chain shortages related to the COVID-19 virus.

​

Net cash used in investing activities for the six months ended June 30, 2021 and 2020 was $0.4 million and $0.7 million, respectively. Cash used in investing activities for the six months ended June 30, 2021 was primarily related to leasehold improvements at our new manufacturing and warehouse facility. Cash used in investing activities for the six months ended June 30, 2020 was primarily related to the purchase of office equipment, IT infrastructure, and leasehold improvements related to our expansion into the second floor at our prior corporate headquarters.

​

Net cash used in financing activities for the six months ended June 30, 2021 was $2.2 million compared with net cash provided by financing activities of $0.2 million for the same period in 2020. Net cash used in financing activities for the six months ended June 30, 2021 was primarily due to purchases of treasury stock. Net cash provided by financing activities for the six months ended June 30, 2020 was primarily due to proceeds from employee stock option purchases.

​

We believe our cash and cash equivalents, together with anticipated cash flow from operations will be sufficient to meet our working capital, and capital expenditure requirements for at least the next twelve months. In making this assessment, we considered the following:

​

| ● | Our cash and cash equivalents balance at June 30, 2021 of $32.3 million;

| ● | Our working capital balance of $52.9 million;

| ● | Our projected income and cash flows for the next 12 months.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

​

Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America.

​

Please refer to the “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and Note 2 to the Consolidated Financial Statements located within our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on February 25, 2021.

​

OFF BALANCE SHEET ARRANGEMENTS

​

The Company had no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders.

​

RISKS AND UNCERTAINTIES

​

In December 2019, a novel Coronavirus disease (“COVID-19”) was reported and on March 11, 2020, the World Health Organization characterized COVID-19 as a pandemic. While the Company did not incur significant disruptions to its operations during the three and six months ended June 30, 2021 from COVID-19, it is unable at this time to predict the impact that COVID-19 will have on its business, financial position and operating results in future periods due to numerous uncertainties. The Company has been and continues to closely monitor the impact of the pandemic on all aspects of its business.

22

​

Table of Contents

​

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

​

In the ordinary course of business, we are exposed to certain market risks, including changes in interest rates. Uncertainties that are either non-financial or non-quantifiable such as political, economic, tax, other regulatory, or credit risks, including healthcare reimbursement practices, are not included in the following assessment of market risks.

​

ITEM 4. CONTROLS AND PROCEDURES

​

Disclosure Controls and Procedures

​

Our management, with the participation of our Chief Executive Officer (CEO) and Chief Financial Officer (CFO), has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (Exchange Act)), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our CEO and CFO have concluded that as of June 30, 2021, our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission (SEC), and that such information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure.

​

In designing and evaluating the disclosure controls and procedures and internal control over financial reporting, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures and internal control over financial reporting must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

​

Changes in Internal Control Over Financial Reporting

​

During the three months ended June 30, 2021, there were no changes that materially affected or are reasonably likely to affect our internal control over financial reporting.

​

23

​

Table of Contents

​

PART II. OTHER INFORMATION

​

ITEM 1. LEGAL PROCEEDINGS

​

We are not a party to any material pending legal proceedings.

​

ITEM 1A. RISK FACTORS

​

There have been no material changes in the risk factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on February 25, 2021.

​

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

​

Items 2(a) and 2(b) are not applicable.

​

(c) Stock Repurchases.

​

Issuer Purchases of Equity Securities

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | (a) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Total | ​ | (b) | ​ | (c) | ​ | (d)
​ | ​ | Number of | ​ | Average | ​ | Total Number of | ​ | Approximate Dollar
​ | ​ | Shares | ​ | Price Paid | ​ | Shares Purchased as Part of | ​ | Value (in thousands) of Shares that may
​ | ​ | Purchased | ​ | per Share | ​ | Publicly Announced Program | ​ | yet be Purchased under the Program
March 8 to June 31, 2021 |  | 140,179 | ​ | $ | 15.12 |  | 140,179 | ​ | $ | 7,880

​

On March 8, 2021, our Board of Directors approved a program to repurchase up to $10.0 million of our common stock at prevailing market prices either in the open market or through privately negotiated transactions through September 8, 2021. From the inception of the plan through June 30, 2021, the Company purchased 140,179 shares of our common stock for $2.1 million or an average price of $15.12 per share.

​

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

​

None.

​

ITEM 4. MINE SAFETY DISCLOSURES

​

N/A

​

ITEM 5. OTHER INFORMATION

​

None.

​

​

24

​

Table of Contents

ITEM 6. EXHIBITS

​

Exhibit Number |  | Description
31.1* |  | Certification of Chief Executive Officer Pursuant to Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of Sarbanes-Oxley Act of 2002
​ | ​ | ​
31.2* |  | Certification of Chief Financial Officer Pursuant to Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of Sarbanes-Oxley Act of 2002
​ | ​ | ​
32.1* |  | Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
​ | ​ | ​
32.2* |  | Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
​ | ​ | ​
101.INS* |  | XBRL Instance Document
101.SCH* |  | XBRL Taxonomy Extension Schema Document
101.CAL* |  | XBRL Taxonomy Calculation Linkbase Document
101.LAB * |  | XBRL Taxonomy Label Linkbase Document
101.PRE * |  | XBRL Presentation Linkbase Document
101.DEF * |  | XBRL Taxonomy Extension Definition Linkbase Document

*Filed herewith

​

​

25

​

Table of Contents

SIGNATURES

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

​

| ZYNEX, INC.
​ | ​
| /s/ Daniel J. Moorhead
Dated: July 29, 2021 | Daniel J. Moorhead
| Chief Financial Officer
| (Principal Financial and Accounting Officer)

​

​

26